Marker Therapeutics (MRKR) EV/EBIT: History & Chart

Marker Therapeutics, Inc.(MRKR)

Biotechnology · Houston, TX

$1.01-0.05 (-4.72%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Marker Therapeutics, Inc.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology. This method involves producing T cells that are not genetically modified but are specifically designed to target tumors. These specialized T cells can identify multiple antigens associated with tumors, allowing them to effectively eliminate cancer cells that express these markers. Marker Therapeutics' MultiTAA-specific T cell therapies encompass patient-derived (autologous) T cells for treating lymphoma and various solid tumors, as well as donor-derived (allogeneic) T cells for acute myeloid leukemia and acute lymphoblastic leukemia. They also provide "off-the-shelf" solutions applicable to a range of diseases. In addition to T cell therapies, the company is advancing peptide-based immunotherapeutic vaccines. This pipeline includes TPIV100/110, developed to combat breast and ovarian cancer cells, and TPIV200, which is currently undergoing Phase 2 clinical trials for the treatment of breast and ovarian cancers. Founded in 1999, Marker Therapeutics maintains its headquarters in Houston, Texas.

Houston, TX

5 employees

www.markertherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Juan F. Vera

View full financials

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Marker Therapeutics, Inc. (MRKR)	$16.84M	N/A	N/A	N/A	N/A
TScan Therapeutics, Inc. (TCRX)vs ›	$16.82M	N/A	N/A	N/A	N/A
Palatin Technologies, Inc. (PTN)vs ›	$16.74M	N/A	197.54x	1437.98x	1437.98x
Bionano Genomics, Inc. (BNGO)vs ›	$16.64M	N/A	N/A	N/A	N/A
PAVmed Inc. (PAVM)vs ›	$17.07M	N/A	N/A	N/A	N/A
Dyadic International, Inc. (DYAI)vs ›	$16.52M	N/A	188.96x	135.60x	135.60x
Lipocine Inc. (LPCN)vs ›	$17.31M	N/A	19.21x	19.21x	19.21x
Cosmos Health Inc. (COSM)vs ›	$17.39M	N/A	64.12x	126.81x	126.81x
BioCardia, Inc. (BCDA)vs ›	$15.78M	N/A	33.55x	33.49x	33.49x
Allarity Therapeutics, Inc. (ALLR)vs ›	$15.68M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EV/EBIT RATIO

TTM

Marker Therapeutics, Inc. (MRKR)

$16.84M

N/A

TScan Therapeutics, Inc. (TCRX)vs ›

$16.82M

N/A

Palatin Technologies, Inc. (PTN)vs ›

$16.74M